Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

GlobeNewsWire

06 Aug 2026, 11:48 UTC · 2h ago

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

What the story claims

3 claims · each scored for market impact

What matters in this story

1
argenx has commenced a tender offer to acquire all outstanding shares of Forte Biosciences for $77.00 per share in cash. — A definite cash acquisition offer typically causes the target's stock price to converge immediately toward the offer price.
+0.90
2
The Forte Board of Directors has recommended that stockholders accept the offer and tender their shares. — Board endorsement significantly reduces the likelihood of a deal collapse or a competing bid, increasing certainty of completion.
+0.40
3
The acquisition is subject to a 'Minimum Condition' requiring more than 50% of shares to be tendered and HSR antitrust clearance. — These conditions introduce a small amount of execution risk and regulatory uncertainty before the deal can close.
-0.20

Which stocks this story touches

6 related stories

Reuters
2h ago
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
- acquisition
- biotech
- m and a
Read

argenx Announces Commence… — FBRX +1.00 | NewsImpactScreener

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

What matters in this story

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

What matters in this story

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

How each ticker is affected

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Precise Biometrics AB (publ) (PRBCF) Discusses Merger Strategy With Fingerprint Cards and Use of Rights Issue Proceeds Transcript

Kenvue Posts Higher Profit, Sales as Turnaround Continues

Radian Group: The Rare Time Diversification Does Not Pay Off (Rating Downgrade)

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

UL Solutions: A Test For The Test Business

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

What matters in this story

Next reads from the same story arc

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

What matters in this story

Next reads from the same story arc

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition

How each ticker is affected

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Precise Biometrics AB (publ) (PRBCF) Discusses Merger Strategy With Fingerprint Cards and Use of Rights Issue Proceeds Transcript

Kenvue Posts Higher Profit, Sales as Turnaround Continues

Radian Group: The Rare Time Diversification Does Not Pay Off (Rating Downgrade)

AstraZeneca may buck a decade of pharma strategy to buy U.S. scale

UL Solutions: A Test For The Test Business